BDC Capital's Thrive Venture Fund joined to lead the extension. Congruence Therapeutics has secured an additional $20 million CAD ($15 million USD) for its Series A round. The extension saw BDC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback